bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day Read more about bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day
bluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation Read more about bluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation
bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy Read more about bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy
LentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program Read more about LentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program
bluebird bio Announces Webcast of Gene Therapy Day Read more about bluebird bio Announces Webcast of Gene Therapy Day
bluebird bio Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia Read more about bluebird bio Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia
bluebird bio to Present at Four Upcoming Conferences Read more about bluebird bio to Present at Four Upcoming Conferences
bluebird bio to Present at Wedbush PacGrow Healthcare Conference Read more about bluebird bio to Present at Wedbush PacGrow Healthcare Conference
bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress Read more about bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress
bluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing Read more about bluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing